CRT With His-Pacing: Good Alternative to Biventricular Pacing With HF
His-pacing correcting left bundle branch block is a promising alternative to biventricular pacing in selected patients with heart failure, according to a new study.
Cardiomyopathy
LVEDD <53 mm Linked to LVEF Improvement After Catheter Ablation in HFrEF
Researchers observed that left ventricular end-diastolic diameter <53 mm may independently predict improvement of left ventricular ejection fraction after catheter ablation in persons with HFrEF and persistent atrial fibrillation.
Mavacamten Under Review for Obstructive Hypertrophic Cardiomyopathy
Mavacamten is an oral, selective allosteric inhibitor of cardiac myosin.
Burden of Mendelian Cardiomyopathy Variants in HF of Ischemic Etiology
Patients with heart failure of mostly ischemic etiology were found to have increased burden of mendelian cardiomyopathy variants compared with control individuals.
Predicting Response to CRT Upgrade in Patients With Chronic Right Ventricular Pacing
Underlying heart disease and use of ACE inhibitors were found to be significant predictors of response to cardiac resynchronization therapy upgrade in patients with chronic right ventricular pacing.
Cardiovascular Outcomes in Black vs White Pregnant and Postpartum Women
Cardiovascular outcomes were found to be worse among Black vs White pregnant and postpartum women.
AHA/ACC Urge Shared Decisions in Hypertrophic Cardiomyopathy
Guidelines emphasize importance of discussing all testing and treatment options, risks and benefits of these options.
Hypertrophic Cardiomyopathy: A 2020 AHA/ACC Guideline for Patient Management
What’s new in the first American Heart Association/American College of Cardiology guidelines for hypertrophic cardiomyopathy since 2011?
![AF treatment hinges on the frequency and severity of symptoms, presence of comorbidities, and whether any underlying causes of AF are identifiable. Treatments include pharmacotherapies, medical or surgical interventions, and lifestyle changes, depending on treatment goals. Most commonly, treatment focuses on controlling heart rate or rhythm while reducing the risk of blood clots.[9] Pharmacotherapies for AF include beta blockers, calcium channel blockers, antiarrhythmics, and anticoagulants. A 2013 AHRQ (Agency for Healthcare Research and Quality) review comparing rate vs rhythm control strategies found comparable efficacy between the 2 in all-cause mortality, cardiovascular mortality, stroke, and bleeding events; however, rate-control strategies were associated with fewer cardiovascular hospitalizations and fewer adverse events.[9] A review from 2015 suggests all patients should receive rate control, with the need for maintenance of sinus rhythm determined on an individual patient basis.[10]](https://3fvcugvijkt9bj7w3wf2t712-wpengine.netdna-ssl.com/wp-content/uploads/sites/17/2019/01/slideshowsizeatrialfibrillati_1061307-544x306.jpg)
Catheter Ablation May Be Superior to MRC for Improving LVEF in Persistent AF With Systolic Heart Failure
Catheter ablation was found to be superior to medical rate control for improving LVEF long term in patients with atrial fibrillation and systolic heart failure.
Ventricular Tachycardia Substrate Ablation During Sinus Rhythm Associated With Few Complication, Low Mortality
Substrate ablation during sinus rhythm was found to be associated with low rates of procedural complications and early mortality.
- Loading...
Loading...
Loading... 
Loading...